Kornej, Jelena
Huang, Qiuxi
Preis, Sarah R.
Lubitz, Steven A.
Ko, Darae
Murabito, Joanne M.
Benjamin, Emelia J.
Trinquart, Ludovic
Funding for this research was provided by:
H2020 Marie Skłodowska-Curie Actions (838259)
National Institutes of Health (5R01HL128914-04, 1R01HL139731, 2R01 HL092577; 1R01 HL141434 01A1; 2U54HL120163; 1R01AG066010)
American Heart Association (18SFRN34250007)
American College of Cardiology Foundation (Research Fellowship in Cardiovascular Diseases and Cardiometabolic Disorders)
American Heart Association (AHA_18SFRN34110082, 18SFRN34150007)
Article History
Received: 8 March 2021
Accepted: 15 June 2021
First Online: 29 July 2021
Declarations
:
: All Framingham Heart Study participants provided written informed consent at each examination, and all study protocols have been approved by the Institutional Review Board of Boston University School of Medicine.
: Not applicable.
: Dr. Lubitz receives sponsored research support from Bristol Myers Squibb/Pfizer, Bayer AG, Boehringer Ingelheim, Fitbit, and IBM and has consulted for Bristol Myers Squibb/Pfizer, Bayer AG, and Blackstone Life Sciences. The other authors have no competing interests to declare.